Medivir AB (OSTO:MVIR)

Q4 2025 Medivir AB Earnings Call Transcript

Feb 18, 2026 / 01:00 PM GMT

Release Date Price: kr1.46 (+46.00%)

Transcript

Key Points

Positve

Medivir AB (FRA:MVR0) has made significant progress in its pipeline, particularly with the initiation of clinical development for MIB 7-Eleven in osteogenesis imperfecta, a strategically important indication.
The company has received orphan drug designation from the FDA for MV 7-Eleven, which could expedite its development and approval process.
The collaboration with Doctorhong and the Korean Cancer Study Group is advancing well, with eight hospitals selected to participate in the study, indicating strong interest and support.
Medivir's partner, Vet Bolics, has shown promising results in a proof of concept study for MV 701 in periodontal disease in dogs, with 20% of subjects already recruited for the next study.
The company has a strong financial position, bolstered by a recent directed share issue, allowing continued development of key programs like MB 7-Eleven and Fostrox.

Negative

There are no approved systemic treatments for osteogenesis imperfecta, highlighting the challenges Medivir faces in developing a first-in-class treatment.
The failure of the phase 3 study for antisclerostin in OI indicates potential hurdles in developing effective treatments for this condition.
The company's operating loss for Q4 was higher than the previous year, partly due to a write-down of the Brina pump project.
The development and regulatory milestones for VBX 1,000 are described as small, indicating limited immediate financial returns from this program.
The timeline for the initiation of the phase 2 proof of concept study for MF 7-Eleven remains uncertain, with regulatory approvals still pending.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

MEDIVIR.ST - Medivir AB
Q4 2025 Medivir AB Earnings Call
Feb 18, 2026 / 01:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
For 2025 for the first part of the conference during the questions and answers session, participants are able to ask questions by dialing #5 on their telephone keypad. Now I will hand the conference over to CEO Jens Lindbergh. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you. Welcome everyone to the Medevier quarterly results webcast.

We look back at a very eventful quarter marked by great progress and very optimistic outlook to the future. And today we very much look forward to sharing more details about the great progress, but also in our pipeline, but also how

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.